Search

Your search keyword '"Peters, Femke P."' showing total 187 results
Start Over Author "Peters, Femke P."
187 results on '"Peters, Femke P."'

2. Development and multicenter validation of a multiparametric imaging model to predict treatment response in rectal cancer

Author

Schurink, Niels W., van Kranen, Simon R., van Griethuysen, Joost J. M., Roberti, Sander, Snaebjornsson, Petur, Bakers, Frans C. H., de Bie, Shira H., Bosma, Gerlof P. T., Cappendijk, Vincent C., Geenen, Remy W. F., Neijenhuis, Peter A., Peterson, Gerald M., Veeken, Cornelis J., Vliegen, Roy F. A., Peters, Femke P., Bogveradze, Nino, el Khababi, Najim, Lahaye, Max J., Maas, Monique, Beets, Geerard L., Beets-Tan, Regina G. H., and Lambregts, Doenja M. J.

Published
2023
Full Text
View/download PDF

6. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer

Author

Fokas, Emmanouil, Appelt, Ane, Glynne-Jones, Robert, Beets, Geerard, Perez, Rodrigo, Garcia-Aguilar, Julio, Rullier, Eric, Joshua Smith, J., Marijnen, Corrie, Peters, Femke P., van der Valk, Maxine, Beets-Tan, Regina, Myint, Arthur S., Gerard, Jean-Pierre, Bach, Simon P., Ghadimi, Michael, Hofheinz, Ralf D., Bujko, Krzysztof, Gani, Cihan, Haustermans, Karin, Minsky, Bruce D., Ludmir, Ethan, West, Nicholas P., Gambacorta, Maria A., Valentini, Vincenzo, Buyse, Marc, Renehan, Andrew G., Gilbert, Alexandra, Sebag-Montefiore, David, and Rödel, Claus

Published
2021
Full Text
View/download PDF

7. Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians. Do clinicians know what patients want?

Author

van der Valk, Maxime J.M., van der Sande, Marit E., Toebes, Renee E., Breukink, Stephanie O., Bröker, Mirelle E.E., Doornebosch, Pascal G., Maliko, Nansi, Neijenhuis, Peter A., Marinelli, Andreas W.K.S., Peters, Femke P., Peeters, Koen C.M.J., Beets, Geerard L., Marang-van de Mheen, Perla J., and Hilling, Denise E.

Published
2020
Full Text
View/download PDF

11. Esophageal Gross Tumor Volume Segmentation Using a 3D Convolutional Neural Network

Author

Yousefi, Sahar, Sokooti, Hessam, Elmahdy, Mohamed S., Peters, Femke P., Shalmani, Mohammad T. Manzuri, Zinkstok, Roel T., Staring, Marius, Hutchison, David, Series Editor, Kanade, Takeo, Series Editor, Kittler, Josef, Series Editor, Kleinberg, Jon M., Series Editor, Mattern, Friedemann, Series Editor, Mitchell, John C., Series Editor, Naor, Moni, Series Editor, Pandu Rangan, C., Series Editor, Steffen, Bernhard, Series Editor, Terzopoulos, Demetri, Series Editor, Tygar, Doug, Series Editor, Weikum, Gerhard, Series Editor, Frangi, Alejandro F., editor, Schnabel, Julia A., editor, Davatzikos, Christos, editor, Alberola-López, Carlos, editor, and Fichtinger, Gabor, editor

Published
2018
Full Text
View/download PDF

15. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial

Author

Verweij, Maaike E, primary, Tanaka, Max D, additional, Kensen, Chavelli M, additional, van der Heide, Uulke A, additional, Marijnen, Corrie A M, additional, Janssen, Tomas, additional, Vijlbrief, Tineke, additional, van Grevenstein, Wilhelmina M U, additional, Moons, Leon M G, additional, Koopman, Miriam, additional, Lacle, Miangela M, additional, Braat, Manon N G J A, additional, Chalabi, Myriam, additional, Maas, Monique, additional, Huibregtse, Inge L, additional, Snaebjornsson, Petur, additional, Grotenhuis, Brechtje A, additional, Fijneman, Remond, additional, Consten, Esther, additional, Pronk, Apollo, additional, Smits, Anke B, additional, Heikens, Joost T, additional, Eijkelenkamp, Hidde, additional, Elias, Sjoerd G, additional, Verkooijen, Helena M, additional, Schoenmakers, Maartje M C, additional, Meijer, Gert J, additional, Intven, Martijn, additional, and Peters, Femke P, additional

Published
2023
Full Text
View/download PDF

16. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results

Author

van den Ende, Roy P. J., Peters, Femke P., Harderwijk, Ernst, Rütten, Heidi, Bouwmans, Liza, Berbee, Maaike, Canters, Richard A. M., Stoian, Georgiana, Compagner, Kim, Rozema, Tom, de Smet, Mariska, Intven, Martijn P. W., Tijssen, Rob H. N., Theuws, Jacqueline, van Haaren, Paul, van Triest, Baukelien, Eekhout, Dave, Marijnen, Corrie A. M., van der Heide, Uulke A., and Kerkhof, Ellen M.

Published
2020
Full Text
View/download PDF

17. Baseline and early digital [18F]FDG PET/CT and multiparametric MRI contain promising features to predict response to neoadjuvant therapy in locally advanced rectal cancer patients: a pilot study

Author

Vuijk, Floris A., primary, Feshtali Shahbazi, Shirin, additional, Noortman, Wyanne A., additional, van Velden, Floris H.P., additional, Dibbets-Schneider, Petra, additional, Marinelli, Andreas W.K.S., additional, Neijenhuis, Peter A., additional, Schmitz, Roderick, additional, Ghariq, Eidrees, additional, Velema, Laura A., additional, Peters, Femke P., additional, Smit, Frits, additional, Peeters, Koen C.M.J., additional, Temmink, Sofieke J.D., additional, Crobach, Stijn A.L.P., additional, Putter, Hein, additional, Vahrmeijer, Alexander L., additional, Hilling, Denise E., additional, and de Geus-Oei, Lioe-Fee, additional

Published
2023
Full Text
View/download PDF

18. Long-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach

Author

Custers, Petra A., van der Sande, Marit E., Grotenhuis, Brechtje A., Peters, Femke P., van Kuijk, Sander M. J., Beets, Geerard L., Breukink, Stephanie O., Dutch Watch & Wait Consortium, Custers, Petra A., van der Sande, Marit E., Grotenhuis, Brechtje A., Peters, Femke P., van Kuijk, Sander M. J., Beets, Geerard L., Breukink, Stephanie O., and Dutch Watch & Wait Consortium

Abstract

IMPORTANCE A watch-and-wait approach for patients with rectal cancer and a clinical complete response after neoadjuvant chemoradiotherapy or radiotherapy is associated with better quality of life and functional outcome. Nevertheless, prospective data on both parameters are scarce.OBJECTIVE To prospectively evaluate quality of life and functional outcome, including bowel, urinary, and sexual function, of patients following a watch-and-wait approach. DESIGN, SETTING, AND PARTICIPANTS A total of 278 patients with rectal cancer and a clinical complete response or near-complete response after neoadjuvant chemoradiotherapy or radiotherapy were included in 2 prospective cohort studies: a single-center study (March 2014 to October 2017) and an ongoing multicenter study (from September 2017). Patients were observed by a watch-and-wait approach. Additional local excision or total mesorectal excision was performed for residual disease or regrowth. Data were analyzed between April 1, 2021, and August 27, 2021, for patients with a minimum follow-up of 24 months.MAIN OUTCOMES AND MEASURES Quality of life was evaluated with the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-C30 (EORTC-QLQ-C30), EORTC-QLQ-CR38, or EORTC-QLQ-CR29 and 36-Item Short-Form Health Survey. The score for the questionnaires and 36-Item Short-Form Health Survey ranges from 0 to 100. For some scales, a high score indicates a high level of functioning, and for others it indicates a high level of complaints and symptomatology. Functional outcome was assessed by the Low Anterior Resection Syndrome score, Vaizey incontinence score, International Prostate Symptom Score, International Index of Erectile Function, and Female Sexual Function Index.RESULTS Of 278 patients included, 187 were male (67%), and the median age was 66 years (range, 34-85 years). In the first 24 months, 221 patients (80%) were observed by a watch-and-wait approach without requiring surgery, 18 patients

Published
2023

19. Treatment of locally advanced rectal cancer and synchronous liver metastases:multicentre comparison of two treatment strategies

Author

van Rees, Jan M., Krul, Myrtle F., Kok, Niels F.M., Grünhagen, Dirk J., Kok, E. N.D., Nierop, Pieter M.H., Havenga, Klaas, Rutten, Harm, Burger, Jacobus W.A., de Wilt, Johannes H.W., Hagendoorn, Jeroen, Peters, Femke P., Buijsen, Johannes, Tanis, Pieter J., Verhoef, Cornelis, Kuhlmann, Koert F.D., van Rees, Jan M., Krul, Myrtle F., Kok, Niels F.M., Grünhagen, Dirk J., Kok, E. N.D., Nierop, Pieter M.H., Havenga, Klaas, Rutten, Harm, Burger, Jacobus W.A., de Wilt, Johannes H.W., Hagendoorn, Jeroen, Peters, Femke P., Buijsen, Johannes, Tanis, Pieter J., Verhoef, Cornelis, and Kuhlmann, Koert F.D.

Published
2023

20. Treatment of locally advanced rectal cancer and synchronous liver metastases: multicentre comparison of two treatment strategies

Author

Cancer, MS CGO, Van Rees, Jan M., Krul, Myrtle F., Kok, Niels F.M., Grünhagen, Dirk J., Kok, E. N.D., Nierop, Pieter M.H., Havenga, Klaas, Rutten, Harm, Burger, Jacobus W.A., De Wilt, Johannes H.W., Hagendoorn, Jeroen, Peters, Femke P., Buijsen, Johannes, Tanis, Pieter J., Verhoef, Cornelis, Kuhlmann, Koert F.D., Cancer, MS CGO, Van Rees, Jan M., Krul, Myrtle F., Kok, Niels F.M., Grünhagen, Dirk J., Kok, E. N.D., Nierop, Pieter M.H., Havenga, Klaas, Rutten, Harm, Burger, Jacobus W.A., De Wilt, Johannes H.W., Hagendoorn, Jeroen, Peters, Femke P., Buijsen, Johannes, Tanis, Pieter J., Verhoef, Cornelis, and Kuhlmann, Koert F.D.

Published
2023

21. Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial

Author

Trialbureau Beeld, Cancer, MS CGO, MS MDL 1, MS Medische Oncologie, Pathologie Pathologen staf, MS Radiologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Klinische Fysica RT, MS Radiotherapie, Verweij, Maaike E, Tanaka, Max D, Kensen, Chavelli M, van der Heide, Uulke A, Marijnen, Corrie A M, Janssen, Tomas, Vijlbrief, Tineke, van Grevenstein, Wilhelmina M U, Moons, Leon M G, Koopman, Miriam, Lacle, Miangela M, Braat, Manon N G J A, Chalabi, Myriam, Maas, Monique, Huibregtse, Inge L, Snaebjornsson, Petur, Grotenhuis, Brechtje A, Fijneman, Remond, Consten, Esther, Pronk, Apollo, Smits, Anke B, Heikens, Joost T, Eijkelenkamp, Hidde, Elias, Sjoerd G, Verkooijen, Helena M, Schoenmakers, Maartje M C, Meijer, Gert J, Intven, Martijn, Peters, Femke P, Trialbureau Beeld, Cancer, MS CGO, MS MDL 1, MS Medische Oncologie, Pathologie Pathologen staf, MS Radiologie, Epi Kanker Team C, JC onderzoeksprogramma Kanker, Klinische Fysica RT, MS Radiotherapie, Verweij, Maaike E, Tanaka, Max D, Kensen, Chavelli M, van der Heide, Uulke A, Marijnen, Corrie A M, Janssen, Tomas, Vijlbrief, Tineke, van Grevenstein, Wilhelmina M U, Moons, Leon M G, Koopman, Miriam, Lacle, Miangela M, Braat, Manon N G J A, Chalabi, Myriam, Maas, Monique, Huibregtse, Inge L, Snaebjornsson, Petur, Grotenhuis, Brechtje A, Fijneman, Remond, Consten, Esther, Pronk, Apollo, Smits, Anke B, Heikens, Joost T, Eijkelenkamp, Hidde, Elias, Sjoerd G, Verkooijen, Helena M, Schoenmakers, Maartje M C, Meijer, Gert J, Intven, Martijn, and Peters, Femke P

Published
2023

24. Treatment of locally advanced rectal cancer and synchronous liver metastases: multicentre comparison of two treatment strategies.

Author

van Rees, Jan M., Krul, Myrtle F., Kok, Niels F. M., Grünhagen, Dirk J., Kok, E. N. D., Nierop, Pieter M. H., Havenga, Klaas, Rutten, Harm, Burger, Jacobus W. A., de Wilt, Johannes H. W., Hagendoorn, Jeroen, Peters, Femke P., Buijsen, Johannes, Tanis, Pieter J., Verhoef, Cornelis, and Kuhlmann, Koert F. D.

Subjects
LIVER cancer, RECTAL cancer
Published
2023
Full Text
View/download PDF

26. Features on Endoscopy and MRI after Treatment with Contact X-ray Brachytherapy for Rectal Cancer: Explorative Results

Author

Custers, Petra A., primary, Maas, Monique, additional, Lambregts, Doenja M. J., additional, Beets-Tan, Regina G. H., additional, Beets, Geerard L., additional, Peters, Femke P., additional, Marijnen, Corrie A. M., additional, van Leerdam, Monique E., additional, Huibregtse, Inge L., additional, and van Triest, Baukelien, additional

Published
2022
Full Text
View/download PDF

27. Baseline and early digital [ 18 F]FDG PET/CT and multiparametric MRI contain promising features to predict response to neoadjuvant therapy in locally advanced rectal cancer patients: a pilot study.

Author

Vuijk, Floris A., Feshtali Shahbazi, Shirin, Noortman, Wyanne A., van Velden, Floris H.P., Dibbets-Schneider, Petra, Marinelli, Andreas W.K.S., Neijenhuis, Peter A., Schmitz, Roderick, Ghariq, Eidrees, Velema, Laura A., Peters, Femke P., Smit, Frits, Peeters, Koen C.M.J., Temmink, Sofieke J.D., Crobach, Stijn A.L.P., Putter, Hein, Vahrmeijer, Alexander L., Hilling, Denise E., and de Geus-Oei, Lioe-Fee

Published
2023
Full Text
View/download PDF

33. Clinical Outcomes after International Referral of Uveal Melanoma Patients for Proton Therapy

Author

Marinkovic, Marina, primary, Pors, Lennart J., additional, van den Berg, Vincent, additional, Peters, Femke P., additional, Schalenbourg, Ann, additional, Zografos, Leonidas, additional, Pica, Alessia, additional, Hrbacek, Jan, additional, Van Duinen, Sjoerd G., additional, Vu, T. H. Khanh, additional, Bleeker, Jaco C., additional, Rasch, Coen R. N., additional, Jager, Martine J., additional, Luyten, Gregorius P. M., additional, and Horeweg, Nanda, additional

Published
2021
Full Text
View/download PDF

36. Planning target volume margin assessment for online adaptive MR-guided dose-escalation in rectal cancer on a 1.5 T MR-Linac

Author

Cancer, Onderzoek Radiotherapie, Fysica Radiotherapie Research, Trialbureau Beeld, Klinische Fysica RT, MS Radiotherapie, Eijkelenkamp, Hidde, Boekhoff, Mick R, Verweij, Maaike E, Peters, Femke P, Meijer, Gert J, Intven, Martijn P W, Cancer, Onderzoek Radiotherapie, Fysica Radiotherapie Research, Trialbureau Beeld, Klinische Fysica RT, MS Radiotherapie, Eijkelenkamp, Hidde, Boekhoff, Mick R, Verweij, Maaike E, Peters, Femke P, Meijer, Gert J, and Intven, Martijn P W

Published
2021

38. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results

Author

Ende, Roy P.J. van den, Peters, Femke P., Harderwijk, Ernst, Rutten, H., Bouwmans, Liza, Berbee, Maaike, Heide, Uulke A. van der, Kerkhof, Ellen M., Ende, Roy P.J. van den, Peters, Femke P., Harderwijk, Ernst, Rutten, H., Bouwmans, Liza, Berbee, Maaike, Heide, Uulke A. van der, and Kerkhof, Ellen M.

Abstract

Contains fulltext : 217402.pdf (publisher's version ) (Open Access)

Published
2020

39. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial : Dutch results

Author

Van Den Ende, Roy P.J., Peters, Femke P., Harderwijk, Ernst, Rütten, Heidi, Bouwmans, Liza, Berbee, Maaike, Canters, Richard A.M., Stoian, Georgiana, Compagner, Kim, Rozema, Tom, De Smet, Mariska, Intven, Martijn P.W., Tijssen, Rob H.N., Theuws, Jacqueline, Van Haaren, Paul, Van Triest, Baukelien, Eekhout, Dave, Marijnen, Corrie A.M., Van Der Heide, Uulke A., Kerkhof, Ellen M., Van Den Ende, Roy P.J., Peters, Femke P., Harderwijk, Ernst, Rütten, Heidi, Bouwmans, Liza, Berbee, Maaike, Canters, Richard A.M., Stoian, Georgiana, Compagner, Kim, Rozema, Tom, De Smet, Mariska, Intven, Martijn P.W., Tijssen, Rob H.N., Theuws, Jacqueline, Van Haaren, Paul, Van Triest, Baukelien, Eekhout, Dave, Marijnen, Corrie A.M., Van Der Heide, Uulke A., and Kerkhof, Ellen M.

Published
2020

40. Radiotherapy quality assurance for mesorectum treatment planning within the multi-center phase II STAR-TReC trial: Dutch results

Author

MS Radiotherapie, Cancer, Klinische Fysica RT, Van Den Ende, Roy P.J., Peters, Femke P., Harderwijk, Ernst, Rütten, Heidi, Bouwmans, Liza, Berbee, Maaike, Canters, Richard A.M., Stoian, Georgiana, Compagner, Kim, Rozema, Tom, De Smet, Mariska, Intven, Martijn P.W., Tijssen, Rob H.N., Theuws, Jacqueline, Van Haaren, Paul, Van Triest, Baukelien, Eekhout, Dave, Marijnen, Corrie A.M., Van Der Heide, Uulke A., Kerkhof, Ellen M., MS Radiotherapie, Cancer, Klinische Fysica RT, Van Den Ende, Roy P.J., Peters, Femke P., Harderwijk, Ernst, Rütten, Heidi, Bouwmans, Liza, Berbee, Maaike, Canters, Richard A.M., Stoian, Georgiana, Compagner, Kim, Rozema, Tom, De Smet, Mariska, Intven, Martijn P.W., Tijssen, Rob H.N., Theuws, Jacqueline, Van Haaren, Paul, Van Triest, Baukelien, Eekhout, Dave, Marijnen, Corrie A.M., Van Der Heide, Uulke A., and Kerkhof, Ellen M.

Published
2020

41. Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: clinical outcomes with the 'CROSS-regimen' in daily practice.

Author

Cloos-v.Balen, Marissa, Portier, Edmée S H, Fiocco, Marta, Hartgrink, Henk H, Langers, Alexandra M J, Neelis, Karen J, Lips, Irene M, Peters, Femke P, and Slingerland, Marije

Subjects
ESOPHAGEAL cancer, TREATMENT effectiveness, ONCOLOGIC surgery, EXTERNAL beam radiotherapy, CHEMORADIOTHERAPY, CANCER prognosis
Abstract

Background and objectives Since the first results of the Dutch randomized CROSS-trial, neoadjuvant chemoradiotherapy (CRT) using carboplatin and paclitaxel followed by resection for primary resectable nonmetastatic esophageal cancer (EC) has been implemented as standard curative treatment in the Netherlands. The purpose of this retrospective study is to evaluate the clinical outcomes of this treatment in daily practice in a large academic hospital. Methods Medical records of patients treated for primary resectable nonmetastatic EC between May 2010 and December 2015 at our institution were reviewed. Treatment consisted of five weekly courses of carboplatin (area under the curve 2) and paclitaxel (50 mg/m2) with concurrent external beam radiotherapy (23 fractions of 1.8 Gy), followed by transthoracic or transhiatal resection. Data on survival, progression, acute and late toxicity were recorded. Results A total of 145 patients were included. Median follow-up was 43 months. Median overall survival (OS) and progression-free survival (PFS) were 35 (95% confidence interval [CI] 29.8–40.2) and 30 (95% CI 19.7–40.3) months, respectively, with corresponding 3-year OS and PFS of 49.6% (95% CI 40.4–58.8) and 45.6% (95% CI 36.6–54.6). Acute toxicity grade ≥3 was observed in 25.5% of patients. Late adverse events grade ≥3 were seen in 24.8%, mostly esophageal stenosis. Conclusion Neoadjuvant CRT followed by resection for primary resectable nonmetastatic EC in daily practice results in a 3-year OS of 49.6% (95% CI 40.4–58.8) and PFS of 45.6% (95% CI 36.6–54.6), compared with 58% (51–65%) and 51% (43–58%) within the CROSS-trial. The slightly poorer survival in our daily practice group might be due to the presence of less favorable patient and tumor characteristics in daily practice, as is to be expected in daily practice. Toxicity was comparable with that in the CROSS-trial and considered acceptable. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. T 1ρ for Radiotherapy Treatment Response Monitoring in Rectal Cancer Patients: A Pilot Study.

Author

Kooreman, Ernst S., Tanaka, Max, ter Beek, Leon C., Peters, Femke P., Marijnen, Corrie A. M., van der Heide, Uulke A., and van Houdt, Petra J.

Subjects
RECTAL cancer, CANCER patients, PILOT projects, LINEAR accelerators, RADIOTHERAPY
Abstract

Quantitative MRI has the potential to produce imaging biomarkers for the prediction of early response to radiotherapy treatment. In this pilot study, a potential imaging biomarker, the T1ρ relaxation time, is assessed for this purpose. A T1ρ sequence was implemented on a 1.5 T MR-linac system, a system that combines an MRI with a linear accelerator for radiation treatment. An agar phantom with concentrations of 1–4% w/w was constructed for technical validation of the sequence. Phantom images were assessed in terms of short-term repeatability and signal-to-noise ratio. Twelve rectal cancer patients, who were treated with 5 × 5 Gy, were imaged on each treatment fraction. Individual changes in the T1ρ values of the gross tumor volume (GTV) showed an increase for most patients, although a paired t-test comparing values in the GTV from the first to the last treatment fraction showed no statistically significant difference. The phantom measurements showed excellent short-term repeatability (0.5–1.5 ms), and phantom T1ρ values corresponded to the literature values. T1ρ imaging was implemented successfully on the MR-linac, with a repeatability comparable to diagnostic systems, although clinical benefit in terms of treatment response monitoring remains to be demonstrated. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Selected stage IV rectal cancer patients managed by the watch‐and‐wait approach after pelvic radiotherapy: a good alternative to total mesorectal excision surgery?

Author

Custers, Petra A., Hupkens, Britt J. P., Grotenhuis, Brechtje A., Kuhlmann, Koert F. D., Breukink, Stéphanie O., Beets, Geerard L., Melenhorst, Jarno, Beets‐Tan, Regina G. H., Buijsen, Jeroen, Festen, Sebastiaan, de Graaf, Eelco J. R., Haak, Hester E., Hilling, Denise E., Hoff, Christiaan, Intven, Martijn, Komen, Niels, Kusters, Miranda, van Leerdam, Monique E., Peeters, Koen C. M. J., and Peters, Femke P.

Subjects
RECTAL cancer, SURGICAL excision, CANCER patients, RECTAL surgery, RADIOTHERAPY, OVERALL survival
Abstract

Aim: The aim of this study was to assess the clinical and oncological outcome of a selected group of stage IV rectal cancer patients managed by the watch‐and‐wait approach following a (near‐)complete response of the primary rectal tumour after radiotherapy. Method: Patients registered in the Dutch watch‐and‐wait registry since 2004 were selected when diagnosed with synchronous stage IV rectal cancer. Data on patient characteristics, treatment details, follow‐up and survival were collected. The 2‐year local regrowth rate, organ‐preservation rate, colostomy‐free rate, metastatic progression‐free rate and 2‐ and 5‐year overall survival were analysed. Results: After a median follow‐up period of 35 months, local regrowth was observed in 17 patients (40.5%). Nine patients underwent subsequent total mesorectal excision, resulting in a permanent colostomy in four patients. The 2‐year local regrowth rate was 39.9%, the 2‐year organ‐preservation rate was 77.1%, the 2‐year colostomy‐free rate was 88.1%, and the 2‐year metastatic progression‐free rate was 46.7%. The 2‐ and 5‐year overall survival rates were 92.0% and 67.5%. Conclusion: The watch‐and‐wait approach can be considered as an alternative to total mesorectal excision in a selected group of stage IV rectal cancer patients with a (near‐)complete response following pelvic radiotherapy. Despite a relatively high regrowth rate, total mesorectal excision and a permanent colostomy can be avoided in the majority of these patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Management of conjunctival melanoma with local excision and adjuvant brachytherapy

Author

Brouwer, Niels J., primary, Marinkovic, Marina, additional, Peters, Femke P., additional, Hulshof, Maarten C. C. M., additional, Pieters, Bradley R., additional, de Keizer, Rob J. W., additional, Horeweg, Nanda, additional, Laman, Mirjam S., additional, Bleeker, Jaco C., additional, van Duinen, Sjoerd G., additional, Jager, Martine J., additional, Creutzberg, Carien L., additional, and Luyten, Gregorius P. M., additional

Published
2020
Full Text
View/download PDF

49. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

Author

Lunenburg, Carin A T C, Henricks, Linda M, Dreussi, Eva, Peters, Femke P, Fiocco, Marta, Meulendijks, Didier, Toffoli, Giuseppe, Guchelaar, Henk-Jan, Swen, Jesse J, Cecchin, Erika, Schellens, Jan H M, Gelderblom, Hans, Afd Pharmacoepi & Clinical Pharmacology, and Pharmacoepidemiology and Clinical Pharmacology

Subjects
0301 basic medicine, Male, Cancer Research, Radiation-Sensitizing Agents, Databases, Factual, Dihydropyrimidine Dehydrogenase Deficiency, Gastrointestinal Diseases, Gastroenterology, Dihydropyrimidine dehydrogenase deficiency, 0302 clinical medicine, Neoplasms, Medicine, Multicenter Studies as Topic, Aged, 80 and over, Clinical Trials as Topic, Chemoradiotherapy, Middle Aged, Neoplasm Proteins, Oncology, Fluorouracil, 030220 oncology & carcinogenesis, Toxicity, Inactivation, Metabolic, Female, Dihydropyrimidine dehydrogenase, medicine.drug, Adult, medicine.medical_specialty, Antimetabolites, Antineoplastic, Dose, Genotype, 03 medical and health sciences, Young Adult, Internal medicine, Humans, Genetic Predisposition to Disease, Alleles, Capecitabine, Dihydrouracil Dehydrogenase (NADP), Aged, Retrospective Studies, Dose-Response Relationship, Drug, business.industry, medicine.disease, Hematologic Diseases, 030104 developmental biology, Pharmacogenetics, DPYD, business
Abstract

Background Prospective DPYD genotyping prevents severe fluoropyrimidine (FP)-induced toxicity by decreasing dosages in DPYD variant allele carriers. FP dosages in chemoradiation therapy (CRT) are lower than those in other FP-containing regimens. Pharmacogenetic guidelines do not distinguish between regimens, leaving physicians in doubt to apply dose reductions. Our aim was to investigate severe toxicity in DPYD variant allele carriers receiving CRT. Methods Medical records of 828 patients who received FP-based CRT were reviewed from three centres. Severe (grade ≥III) toxicity in DPYD variant allele carriers receiving upfront FP dose reductions according to pharmacogenetic dosing guidelines and DPYD variant allele carriers not receiving FP dose reductions was compared with DPYD wild-type patients receiving standard dose of FPs in CRT. Results DPYD variant allele carriers treated with standard dosages (N = 34) showed an increased risk of severe gastrointestinal (adjusted OR = 2.58, confidence interval [CI] = 1.02–6.53, P = 0.045) or severe haematological (adjusted OR = 4.19, CI = 1.32–13.25, P = 0.015) toxicity compared with wild-type patients (N = 771). DPYD variant allele carriers who received dose reductions (N = 22) showed a comparable frequency of severe gastrointestinal toxicity compared with wild-type patients, but more (not statistically significant) severe haematological toxicity. Hospitalisations for all DPYD variant allele carriers were comparable, independent of dose adjustments; however, the mean duration of hospitalisation was significantly shorter in the dose reduction group (P = 0.010). Conclusions Standard FP dosages in CRT resulted in an increased risk of severe toxicity in DPYD variant allele carriers. We advise to apply FP dose reductions according to current guidelines in DPYD variant allele carriers starting CRT.

Published
2018

50. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Lunenburg, Carin A T C, Henricks, Linda M, Dreussi, Eva, Peters, Femke P, Fiocco, Marta, Meulendijks, Didier, Toffoli, Giuseppe, Guchelaar, Henk-Jan, Swen, Jesse J, Cecchin, Erika, Schellens, Jan H M, Gelderblom, Hans, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Lunenburg, Carin A T C, Henricks, Linda M, Dreussi, Eva, Peters, Femke P, Fiocco, Marta, Meulendijks, Didier, Toffoli, Giuseppe, Guchelaar, Henk-Jan, Swen, Jesse J, Cecchin, Erika, Schellens, Jan H M, and Gelderblom, Hans

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results